Myomo, Inc. Announces the Launch of Myomo Academy at AOPA National Assembly
September 12 2024 - 8:30AM
Business Wire
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the
“Company”), a wearable medical robotics company that offers
increased functionality for those suffering from neurological
disorders and upper-limb paralysis, today announced the official
launch of the Myomo Academy, a comprehensive learning management
system for professionals in Orthotics & Prosthetics (O&P)
and Rehabilitation.
The Myomo Academy is being launched during the 2024 AOPA
(American Orthotic and Prosthetic Association) National Assembly,
which is underway in Charlotte, NC until September 15, 2024.
Attendees are invited to visit Myomo at booth #401 to gain
first-hand insights into the new educational platform and receive
access credentials.
The Myomo Academy is designed to provide ongoing education,
featuring a wide range of courses from introductory to advanced
levels. With a structured curriculum tailored to support Centers of
Excellence and therapy training, these courses will offer easy
access to clinically relevant content and ensure that clinicians
remain at the forefront of upper-extremity myoelectric orthosis
technology.
“We are thrilled to introduce the Myomo Academy as a central
resource for enhancing outcomes and education in O&P and
rehabilitation, and we’re excited to help more clinicians advance
their knowledge of myoelectric orthotics,” said Kathy Sawyers, PT,
ATP, Sr. Director of Clinical Outcomes.
“By leveraging our expertise, we are committed to delivering
exceptional educational content that is unique and not readily
available elsewhere, helping clinicians provide the best care for
their patients,” said Paul R. Gudonis, Chairman and CEO of Myomo,
Inc.
About Myomo, Inc.
Myomo, Inc. is a wearable medical robotics company that offers
improved arm and hand function for those suffering from
neurological disorders and upper limb paralysis. Myomo develops and
markets the MyoPro product line. MyoPro is a powered upper limb
orthosis designed to support the arm and restore function to the
weakened or paralyzed arms of patients suffering from CVA stroke,
brachial plexus injury, traumatic brain or spinal cord injury or
other neuromuscular disease or injury. It is currently the only
marketed device in the U.S. that, sensing a patient’s own EMG
signals through non-invasive sensors on the arm, can restore an
individual’s ability to perform activities of daily living,
including feeding themselves, carrying objects and doing household
tasks. Many are able to return to work, live independently and
reduce their cost of care.
Myomo is headquartered in Boston, Massachusetts, with sales and
clinical professionals across the U.S and representatives
internationally. For more information, please visit
www.myomo.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240912701943/en/
Joseph Chicoskie Director of Marketing Myomo, Inc. Email:
joseph.chicoskie@myomo.com Phone: 833-927-3671 Website:
www.myomo.com
Myomo (AMEX:MYO)
Historical Stock Chart
From Oct 2024 to Nov 2024
Myomo (AMEX:MYO)
Historical Stock Chart
From Nov 2023 to Nov 2024